ArticleCureus2026
Primary Breast Sarcoma: A Case Report at Kuwait Cancer Center and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast sarcomas can be classified as primary (de novo) or, more commonly, secondary to previous radiation therapy for breast cancer or lymphoma. Primary breast sarcoma (PBS) is particularly rare (around 0.1% of all primary breast cancers and <5% of all soft tissue sarcomas) and differs from malignant phyllodes tumors with a worse prognosis. Diagnosis is by triple assessment and ruling out all the differentials (most commonly malignant phyllodes and metaplastic carcinomas) using core biopsy, but sometimes complete surgical excision is needed to confirm the tissue diagnosis. Staging and management of PBS are different from that for breast carcinoma, and they follow the guidelines of soft tissue sarcoma of the trunk and extremities. The standard of care is surgical resection with adequate negative margins (>1 cm for all sarcomas and >3 cm in angiosarcoma and leiomyosarcoma). Axillary staging can be considered only if the core biopsy diagnosis is uncertain (complete excision advised by the pathologist) or in the presence of discordance between clinical/radiological findings and fine-needle cytology of axillary lymph nodes. The role of adjuvant therapy, either radiation or systemic chemotherapy, is highly controversial, but the National Comprehensive Cancer Network (NCCN) guidelines recommend considering adjuvant radiotherapy for cases with positive margins or higher stages. In addition, there is no solid consensus about the benefit of chemotherapy, but some articles reported using it in both adjuvant and neoadjuvant settings. In conclusion, the management should be on a case-by-case basis supported by multidisciplinary team (MDT) approach. The aim of this article is to present a case of PBS with a clinical presentation of rapidly growing locally advanced breast cancer in a 32-year-old woman in the State of Kuwait. Moreover, the authors are presenting an up-to-date review of the limited literature on PBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.